| Bioactivity | Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis[1][2]. | ||||||||||||
| Invitro | Milademetan (DS-3032) can stabilize TP53 and selectively induce CDKNA1, BAX and MDM2 expression in neuroblastoma cells with wild-type TP53[3].Milademetan (DS-3032b) treatment enhances TP53 target gene expression and induces G1 cell cycle arrest, senescence and apoptosis[3].Milademetan (DS-3032b, 0-2000 nM) treatment selectively inhibits viability, proliferation and migration of neuroblastoma cells with wildtype TP53 independently of MYCN status[4]. Cell Viability Assay[4] Cell Line: | ||||||||||||
| Name | Milademetan | ||||||||||||
| CAS | 1398568-47-2 | ||||||||||||
| Formula | C30H34Cl2FN5O4 | ||||||||||||
| Molar Mass | 618.53 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Milademetan
CAS: 1398568-47-2 F: C30H34Cl2FN5O4 W: 618.53
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.